Loading...
ABMD logo

Abiomed, Inc.NasdaqGS:ABMD Aktienübersicht

Marktkapitalisierung US$17.2b
Aktienkurs
n/a
Mein Marktwert
n/v
1Y8.2%
7D0.005%
1D
Wert des Portfolios
​
Siehe

Abiomed, Inc.

NasdaqGS:ABMD Lagerbericht

Marktkapitalisierung: US$17.2b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Abiomed (ABMD) Aktienübersicht

Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. Mehr Details

ABMD grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung0/6
Künftiges Wachstum1/6
Vergangene Leistung4/6
Finanzielle Gesundheit6/6
Dividenden0/6

Belohnungen

Prognostiziertes jährliches Umsatzwachstum 13.08%

Die Erträge stiegen im vergangenen Jahr um 78.9%

Risikoanalyse

Die Erträge werden in den nächsten 3 Jahren voraussichtlich um durchschnittlich 2.5% pro Jahr sinken.

Volatiler Aktienkurs in den letzten 3 Monaten im Vergleich zum US -Markt

Große einmalige Posten, die sich auf die Finanzergebnisse auswirken


ABMD Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Abiomed, Inc. Wettbewerber

Preisentwicklung & Leistung

Zusammenfassung der Höchst- und Tiefststände sowie der Veränderungen der Aktienkurse für Abiomed
Historische Aktienkurse
Aktueller AktienkursUS$381.02
52-Wochen-HochUS$381.99
52-Wochen-TiefUS$219.85
Beta1.4
1 Monat Veränderung0.86%
3 Monate Veränderung55.18%
1 Jahr Veränderung8.18%
3 Jahre Veränderung125.10%
5 Jahre Veränderung103.31%
Veränderung seit IPO6,385.45%

Aktuelle Nachrichten und Updates

Seeking Alpha • Oct 17

Abiomed's Impella low profile sheath gets FDA clearance

The U.S. Food and Drug Administration (FDA) granted 510(k) clearance to Abiomed's (NASDAQ:ABMD) Impella Low Profile Sheath. Compared to the existing 14 French (Fr) sheath used for placement Impella CP, the new sheath maintains the same inner diameter, but reduces the outer diameter by nearly 2 Fr, the company said in a statement on Monday. Abiomed added that due to its smaller size and other advancements, the Low Profile Sheath will facilitate easier Impella insertion and removal, and reduce procedural steps. The company said that it will begin a phased roll-out of the Impella Low Profile Sheath this quarter. The heart pump Impella CP with SmartAssist is approved to treat certain patients with advanced heart failure who are undergoing percutaneous coronary interventions, such as stenting or balloon angioplasty, to reopen blocked coronary arteries, according to the company.

Recent updates

Seeking Alpha • Oct 17

Abiomed's Impella low profile sheath gets FDA clearance

The U.S. Food and Drug Administration (FDA) granted 510(k) clearance to Abiomed's (NASDAQ:ABMD) Impella Low Profile Sheath. Compared to the existing 14 French (Fr) sheath used for placement Impella CP, the new sheath maintains the same inner diameter, but reduces the outer diameter by nearly 2 Fr, the company said in a statement on Monday. Abiomed added that due to its smaller size and other advancements, the Low Profile Sheath will facilitate easier Impella insertion and removal, and reduce procedural steps. The company said that it will begin a phased roll-out of the Impella Low Profile Sheath this quarter. The heart pump Impella CP with SmartAssist is approved to treat certain patients with advanced heart failure who are undergoing percutaneous coronary interventions, such as stenting or balloon angioplasty, to reopen blocked coronary arteries, according to the company.
Seeking Alpha • Sep 28

Abiomed: Correction Offers Good Buying Opportunity

Summary Abiomed’s Impella range of micro heart pumps enjoy rising demand in the marketplace. The company’s OXY-1 System cardiopulmonary support device has strong growth prospect. The company’s revenue will grow at a CAGR of high-single digits in the long term, which will drive the company’s share price significantly higher in the next five years. Abiomed's (ABMD) micro heart pumps enjoy rising demand in the cardiovascular marketplace. I expect the company's Impella range of micro heart pumps will drive the company's long-term revenue growth significantly, and its Impella product pipeline will support long-term revenue growth as well. Long-term growth-oriented investors can buy the company's shares around the current price to maximize their profit. Abiomed develops heart pump products and oxygenation products for patients who are suffering from severe heart disease and in need of hemodynamic support. Its products are used in cath lab by interventional cardiologists and in the heart surgery suite by cardiac surgeons. The company's heart pump products work by improving blood flow and/or performing the pumping function of the heart. Its oxygenation products work by providing sufficient oxygenation to respiratory failure patients. Growth Drivers Impella Heart Pumps Abiomed's Impella micro heart pump product line is its main growth driver. Impella is a percutaneous heart pump that is used to treat CHD (coronary heart disease), and high-risk PCI (percutaneous coronary intervention). Impella has variants which are Impella 2.5, Impella CP, Impella 5.0, Impella LD, Impella 5.5 and Impella RP. These pumps beat competitive products, such as intra-aortic balloon pumps (IABPs) and the TandemHeart device, due to the following reasons: Impella helps CHD and PCI patients maintain proper blood circulation in a better way. Impella offers continued function irrespective of timing or trigger. These pumps offer stability to patients despite the presence of arrhythmias. These pumps can pump up to 2.5 to 6 liters of blood per minute, which provides better cardiac output. According to a report: The heart pump device market is projected to reach USD 5.5 billion by 2026 from USD 2.1 billion in 2021, at a CAGR of 21.6% from 2021 to 2026. Promising product pipeline, increasing number of product approvals and emerging markets are expected to offer growth opportunities in the market during the forecast period. Due to the strong growth prospects of the heart pump market, Abiomed's revenue will continue to grow rapidly in the next five years. OXY-1 System Abiomed's OXY-1 System, which is a compact cardiopulmonary support system, is the company's another growth driver. The system offers respiratory assistance to patients suffering from cardiogenic shock combined with respiratory failure. The machine's oxygen concentrator and pump provide oxygenation to venous blood, and as a result, patients get significant respiratory support. The device performs well in the competitive environment and beat competitor products such as traditional ECMO (extracorporeal membrane oxygenation) machines due to its capability to provide uniform blood flow and superior respiratory support. I expect the device will support Abiomed's long-term revenue growth which primarily comes from Impella. Competition The heart pump industry is characterized by tremendous competition. Abiomed's competitors in this industry include Abbott Laboratories (ABT), Medtronic (MDT), Edwards Lifesciences (EW), Boston Scientific (BSX), LivaNova (LIVN), and Terumo Corporation (TRUMF). Abiomed competes with these companies on the basis of developing innovative heart pump devices, continuity in new product development, and advanced 24 x 7 hospital support. Abiomed's primary competitive advantage is that its current strategy of developing devices in the area of circulatory care is supported by substantial expertise in developing heart pump devices. As a result, the company's heart pump devices enjoy significant demand in the marketplace. The company intends to continue to use its expertise in developing additional circulatory support devices and making enhancements to existing devices, which will support its future revenue growth. The company's another competitive advantage is that its Impella micro heart pump is the only FDA approved heart pump for high-risk PCI, cardiogenic shock, and right ventricular failure. As a result, Impella and its forthcoming variants will continue to drive Abiomed's revenue growth. First Quarter 2023 Financial Results Abiomed reported first quarter 2023 revenue of $277 million, an increase of 10% year-over-year, compared to $253 million in the prior fiscal year period. Non-GAAP net income per diluted share came in at $1.25, an increase of 13.6% year-over-year, compared to $1.10 in the prior fiscal year period. The company delivered strong results for the first quarter of fiscal 2023. Top line grew driven by robust sales across the U.S., Europe and Japan. The company's heart pump product line is witnessing growing adoption since it addresses the challenge of treating heart disease in multiple emergency patient populations in the cath lab and surgical suite. This is driving the company's revenue growth. The company's bottom line grew driven by strong patient utilization across the three regions mentioned above. Abiomed 2.0, the new Abiomed with unparalleled focus on innovating heart and lung repairing devices amid hindrances such as hospital labor shortages, supply chain constraints and contrast media shortages, will boost the company's top and bottom line growth in the next five years. I expect the company's revenue will grow at a CAGR of high single-digits in this time frame.
Seeking Alpha • Sep 16

U.S. FDA gives two approvals to Abiomed Impella heart pumps

Abiomed (NASDAQ:ABMD) said on Friday it had received two approvals from the U.S. Food and Drug Administration related to clinical research of Impella heart pumps for acute myocardial infarction (AMI) cardiogenic shock or heart attack. The FDA has approved the on-label RECOVER IV trial for AMI cardiogenic shock patients. RECOVER IV is a trial that is designed to to achieve a Class I guideline recommendation for Impella use in AMI cardiogenic shock. The FDA has also approved and closed Impella’s prospective AMI cardiogenic shock post-approval study, dubbed Recover III. This study gathered real-world evidence on AMI cardiogenic shock patients treated with Impella between 2017–2019, collecting detailed data including stages of cardiogenic shock, cardiac output and timing of implantation.
Seeking Alpha • Aug 03

Abiomed FQ1 2023 Earnings Preview

Abiomed (NASDAQ:ABMD) is scheduled to announce FQ1 earnings results on Thursday, August 4th, before market open. The consensus EPS Estimate is $1.06 (-3.6% Y/Y) and the consensus Revenue Estimate is $276.46M (+9.4% Y/Y). Over the last 2 years, ABMD has beaten EPS estimates 88% of the time and has beaten revenue estimates 100% of the time. Over the last 3 months, EPS estimates have seen 1 upward revision and 1 downward. Revenue estimates have seen 1 upward revision and 1 downward.
Seeking Alpha • May 17

Abiomed's Profit Growth Slows On R&D, Sales Hold Strong Despite Shortages

ABMD had a decent quarter where revenues grew nicely but profits languished due to sudden growth in R&D spend. Companies like ABMD have to expense R&D, which is not a problem, but a lack of profit growth isn't great given its valuation. The multiple doesn't offer much of a margin of safety, but we recognise the premier product portfolio. Overall, there is a defensive angle for the stock given rate increases, but the valuation is too much of a concern.
Seeking Alpha • Jan 24

Abiomed's Less Troubled 2020 Justifies Multiple, But Medium-Term Headwinds Mean Capital Risk

Abiomed is a company with a superb product in the mid-market space while what appears on the surface is an extremely high multiple. While the multiple appears high at first, it does actually reflect the profile of the company on a more normalised basis, where it is currently experiencing headwinds. The secular outlook is obviously intact, but given the high multiple and the unknown length of the medium-term headwinds, it is not an especially compelling opportunity.
Seeking Alpha • Sep 10

Abiomed: Impella Will Continue To Drive Revenue Growth

Abiomed’s strong growth drivers and advanced product pipeline will boost its long-term revenue growth. The company’s Impella range of micro heart pumps will continue to see increasing adoption globally. Long-term investors can buy the company’s shares around the current price to maximize their gain.
Seeking Alpha • Jul 13

Abiomed: Recovery Mode Has Been Activated - Reiterate Buy Rating

Abiomed has commenced its path to recovery on the charts, following a big hit in April this year. Key tension points for ABMD's share price lie in its Impella sales volume, which continues to gain traction sequentially as we walk through this year. Shares are trading at a premium to historical averages and to the peer group, thus balancing the investment case. Nonetheless, we are bullish on ABMD shares and see an investment debate that is skewed in investors' favour. Here, we present all of the necessary moving parts in the investment debate for the benefit of investors' own reasoning.

Aktionärsrenditen

ABMDUS Medical EquipmentUS Markt
7D0.005%6.1%-3.3%
1Y8.2%-19.2%22.3%

Rendite im Vergleich zur Industrie: ABMD übertraf die Branche US Medical Equipment , die im vergangenen Jahr eine Rendite von -19.2 erzielte.

Rendite vs. Markt: ABMD übertraf den Markt US, der im vergangenen Jahr eine Rendite von 22.3 erzielte.

Preisvolatilität

Is ABMD's price volatile compared to industry and market?
ABMD volatility
ABMD Average Weekly Movement14.6%
Medical Equipment Industry Average Movement8.6%
Market Average Movement7.2%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.1%

Stabiler Aktienkurs: Der Aktienkurs von ABMD war in den letzten 3 Monaten im Vergleich zum US -Markt volatil.

Volatilität im Zeitverlauf: ABMDDie wöchentliche Volatilität der Aktie ist im vergangenen Jahr von 9% auf 15% gestiegen.

Über das Unternehmen

GegründetMitarbeiterCEOWebsite
19812,003Mike Minoguewww.abiomed.com

Abiomed, Inc.'s Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Abiomed im Vergleich zum Marktanteil des Unternehmens?
ABMD grundlegende Statistiken
MarktanteilUS$17.19b
Gewinn(TTM)US$266.76m
Umsatz(TTM)US$1.07b
64.4x
Kurs-Gewinn-Verhältnis
16.0x
Kurs-Umsatz-Verhältnis

Ist ABMD zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
ABMD Gewinn- und Verlustrechnung (TTM)
EinnahmenUS$1.07b
Kosten der EinnahmenUS$200.59m
BruttogewinnUS$873.51m
Sonstige AusgabenUS$606.74m
GewinnUS$266.76m

Zuletzt gemeldete Gewinne

Sep 30, 2022

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)5.91
Bruttomarge81.32%
Nettogewinnspanne24.84%
Schulden/Eigenkapital-Verhältnis0%

Wie hat sich ABMD auf lange Sicht entwickelt?

Historische Performance und Vergleiche

Unternehmensanalyse und Finanzdaten Status

DatenZuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse2022/12/24 10:29
Aktienkurs zum Tagesende2022/12/21 00:00
Gewinne2022/09/30
Jährliche Einnahmen2022/03/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

PaketDatenZeitrahmenBeispiel US-Quelle *
Finanzdaten des Unternehmens10 Jahre
  • Gewinn- und Verlustrechnung
  • Kapitalflussrechnung
  • Bilanz
Konsensschätzungen der Analysten+3 Jahre
  • Finanzielle Vorausschau
  • Kursziele der Analysten
Marktpreise30 Jahre
  • Aktienkurse
  • Dividenden, Splits und Aktionen
Eigentümerschaft10 Jahre
  • Top-Aktionäre
  • Insiderhandel
Verwaltung10 Jahre
  • Das Führungsteam
  • Direktorium
Wichtige Entwicklungen10 Jahre
  • Ankündigungen des Unternehmens

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Abiomed, Inc. wird von 21 Analysten beobachtet. 3 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

AnalystEinrichtung
Lawrence NeiborBaird
Jan WaldBenchmark Company
Isaac RoGoldman Sachs